Skip to content
Peptide research

Pentapeptide-18

Also known as Leuphasyl
Category
Skin & Cosmetic
Administration routes
Topical
Regulatory status
Cosmetic ingredient

What it is

A synthetic pentapeptide in wrinkle serums that mimics enkephalins to relax facial muscles, marketed as a Botox alternative. Evidence is limited to small, open-label, manufacturer-funded trials with modest results, not blinded studies; other benefits are speculative, from lab or computational work. No serious adverse effects are reported, but long-term safety data are scarce; it remains unapproved, sold as a cosmetic ingredient, not a research peptide.

Read Full record

Studied uses & evidence

Studied uses(6)

  • Reduction of expression wrinkles (forehead lines, crow's feet, frown lines)

    Speculative

    Published human studies exist, including a 20-person uncontrolled study in 2014; rigorous evidence isolating the peptide's effect remains limited.

  • Synergistic wrinkle reduction when combined with Argireline (Acetyl Hexapeptide-8)

    Speculative

    Marketing rationale only; no published study has tested the combination in humans or cells.

  • Non-invasive Botox-like muscle relaxation without loss of facial expressivity

    Speculative

    Mechanism-based only; no human EMG studies or comparisons with botulinum toxin exist.

Evidence limits

Evidence Level
Moderate

The clinical evidence for Pentapeptide-18 is consistent but limited in scope and rigor. The manufacturer's 2005 in-vivo studies (Lipotec) across three arms (14-15 volunteers each, 28 days) demonstrated 11.64% wrinkle reduction for Leuphasyl alone and 24.62% for the combination with Argireline. Dragomirescu et al. (2014) independently confirmed efficacy at 2% concentration in 20 volunteers over 2 months (34.7% frontal, 28.4% periorbital wrinkle reduction) and established a dose-response threshold. Two 2024 studies by Pawlowska et al. showed improved delivery via nanoparticle formulations. Park et al. (2020) added anti-melanogenic evidence using D-tyrosine derivatives. All studies report excellent safety with no adverse effects. However, there are no large RCTs, no long-term safety data beyond 2 months, and most core efficacy claims rest on manufacturer-sponsored data. The evidence is sufficient for cosmetic claims but far below pharmaceutical standards.

Benefits = confidence in the evidence: High · Medium · Low · Speculative (High requires human randomized trials for that specific benefit)

Cautions & risk summary

General cautions

  • Pregnancy or breastfeeding

    Absolute

    No human reproductive safety data exists for this peptide. Effects on fetal development are unknown.

  • Children under 18

    Absolute

    No pediatric safety data. Not recommended for use in minors.

  • Known hypersensitivity

    Absolute

    Discontinue immediately if allergic reaction occurs (rash, swelling, difficulty breathing).

Risk summary(4)

Risks = level of concern: High · Moderate · Low · Theoretical

  • No known serious adverse effects

    Low
  • Potential skin sensitivity in hypersensitive individuals

    Low
  • Limited long-term safety data

    Moderate
  • Theoretical opioid receptor activation

    Theoretical
Safety & interactions in Full record

Further reading

Read Full record

This is educational content compiled from published research, not medical advice. Always consult a licensed healthcare provider before using any peptide. Medical disclaimer

Compiled from published research indexed through March 2026.